PT-141 (Bremelanotide)
Melanocortin receptor agonist derived from Melanotan 2, developed to study centrally mediated sexual arousal and melanocortin neuroendocrine pathways.
Explore calculators for this peptide
Use the Peptide Research Tools to experiment with mcg/kg exposure curves for PT‑141, including on‑demand versus intermittent paradigms. All values are placeholders and must be aligned with your own research protocol.
Open PT-141 in calculators →
Research frame & potential applications
PT‑141 (Bremelanotide) is a synthetic peptide that activates central melanocortin receptors, particularly MC3R and MC4R, to modulate sexual desire and arousal without directly affecting nitric oxide pathways.
It has been clinically evaluated for hypoactive sexual desire disorder (HSDD) in women and erectile dysfunction in men, and is used experimentally to dissect melanocortin involvement in reward, appetite and autonomic regulation.
Research areas & putative benefits
How PT‑141 is used to interrogate melanocortin and sexual function biology.
- Studying central mechanisms of sexual desire and arousal independent of penile vascular NO signalling.
- Evaluating treatment options for hypoactive sexual desire disorder and certain forms of sexual dysfunction.
- Mapping melanocortin cross‑talk with appetite control, reward pathways and mood regulation.
- Exploring acute autonomic responses, including blood pressure and heart‑rate effects of MC agonism.
Mechanism stack
From receptor binding to behavioural and autonomic responses.
Central melanocortin
MC3R/MC4R agonism
PT‑141 binds melanocortin receptors in the CNS, especially MC3R and MC4R in hypothalamic and limbic regions, influencing sexual desire, autonomic tone and energy balance.
Sexual arousal
Central, not purely vascular
Unlike PDE5 inhibitors, PT‑141 exerts its effects centrally, modulating neural circuits that govern sexual interest and arousal, which can enhance responsiveness independently of pure vasodilation.
Autonomic effects
BP & nausea
Melanocortin receptor engagement can acutely increase blood pressure and cause nausea, likely through hypothalamic and brainstem autonomic centres, defining key tolerability constraints in clinical use.
Relation to MT‑2
Refined melanocortin profile
PT‑141 is structurally related to Melanotan 2 but designed to emphasise central sexual‑arousal effects over strong pigmentation, though some tanning and flushing signals can still occur.
Evidence snapshot
Findings from clinical sexual‑dysfunction trials and mechanistic work.
| Model / context | Observation | Notes |
|---|---|---|
|
Female HSDD trials
Clinical
|
Subcutaneous PT‑141 improves patient‑reported desire and distress scores versus placebo in some women with hypoactive sexual desire disorder, with onset typically within hours of dosing. | Basis for on‑demand approved use in certain jurisdictions. |
|
Male erectile dysfunction
Mechanistic clinical
|
PT‑141 produces erectile responses in some men, including partial responders or non‑responders to PDE5 inhibitors, via central pathways. | Highlights a mechanistically distinct route from pure vascular agents. |
|
Adverse‑effect profile
Safety
|
Nausea, flushing, transient increases in blood pressure and headache are among the most common side‑effects, particularly at higher exposures. | Dose‑limiting in both research and clinical contexts; contraindicated in uncontrolled hypertension and cardiovascular disease. |
|
Melanocortin system mapping
Neuroendocrine
|
PT‑141 has been used as a probe to dissect MC4R‑linked pathways that couple energy balance and sexual function, informing broader melanocortin biology. | Provides a pharmacological handle on intertwined appetite, reward and reproductive circuits. |
Risk frame & unknowns
Safety and translational considerations for PT‑141.
Important research caveats
- Cardiovascular effects (BP and heart‑rate changes) require careful screening and monitoring in at‑risk populations.
- Long‑term frequent use outside controlled indications has not been deeply characterised.
- Co‑use with other melanocortin agonists (e.g. MT‑2) could potentiate both desired and adverse effects in unpredictable ways.
- Psychological and relational context strongly modulates subjective outcomes, adding variability to research endpoints.
This dossier summarizes mechanistic and clinical findings on PT‑141 (Bremelanotide) for scientific and educational purposes only.
It does not provide medical advice, treatment guidance or dosing recommendations.